Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

2.

Pharmacogenetics studies in STAR*D: strengths, limitations, and results.

Laje G, Perlis RH, Rush AJ, McMahon FJ.

Psychiatr Serv. 2009 Nov;60(11):1446-57. doi: 10.1176/appi.ps.60.11.1446.

3.

Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort.

Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ.

Am J Psychiatry. 2007 Aug;164(8):1181-8.

PMID:
17671280
4.

SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.

Shiroma PR, Drews MS, Geske JR, Mrazek DA.

Am J Geriatr Psychiatry. 2014 Nov;22(11):1140-8. doi: 10.1016/j.jagp.2013.02.012. Epub 2013 Aug 20.

5.

The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort.

Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ, Paddock S.

Biol Psychiatry. 2008 Jun 15;63(12):1103-10. doi: 10.1016/j.biopsych.2007.10.026. Epub 2008 Jan 11.

6.

Pharmacogenomics with antidepressants in the STAR*D study.

Lin E, Chen PS.

Pharmacogenomics. 2008 Jul;9(7):935-46. doi: 10.2217/14622416.9.7.935. Review.

PMID:
18597655
7.

Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.

Perlis RH, Purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH, Smoller JW.

Arch Gen Psychiatry. 2007 Jun;64(6):689-97.

PMID:
17548750
8.

Pharmacogenetics in major depression: a comprehensive meta-analysis.

Niitsu T, Fabbri C, Bentini F, Serretti A.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:183-94. doi: 10.1016/j.pnpbp.2013.05.011. Epub 2013 Jun 1. Erratum in: Prog Neuropsychopharmacol Biol Psychiatry. 2013 Dec 2;47:118-9.

PMID:
23733030
9.

Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.

Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, Müller-Myhsok B, Holsboer F, Binder EB.

Neuropsychopharmacology. 2010 Feb;35(3):727-40. doi: 10.1038/npp.2009.180. Epub 2009 Nov 18.

10.

Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.

GENDEP Investigators.; MARS Investigators.; STAR*D Investigators..

Am J Psychiatry. 2013 Feb;170(2):207-17. doi: 10.1176/appi.ajp.2012.12020237.

PMID:
23377640
11.

A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression.

Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Müller-Myhsok B.

Arch Gen Psychiatry. 2009 Sep;66(9):966-75. doi: 10.1001/archgenpsychiatry.2009.95.

12.

Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders.

Helton SG, Lohoff FW.

Pharmacogenomics. 2015;16(5):541-53. doi: 10.2217/pgs.15.15. Review.

PMID:
25916524
13.

Genetic studies of drug response and side effects in the STAR*D study, part 2.

Garriock HA, Hamilton SP.

J Clin Psychiatry. 2009 Sep;70(9):1323-5. doi: 10.4088/JCP.09ac05522. No abstract available.

PMID:
19818256
14.

Genetic markers of suicidal ideation emerging during citalopram treatment of major depression.

Laje G, Paddock S, Manji H, Rush AJ, Wilson AF, Charney D, McMahon FJ.

Am J Psychiatry. 2007 Oct;164(10):1530-8.

PMID:
17898344
15.

Pharmacogenomics of antidepressant drugs.

Horstmann S, Binder EB.

Pharmacol Ther. 2009 Oct;124(1):57-73. doi: 10.1016/j.pharmthera.2009.06.007. Epub 2009 Jun 27. Review.

PMID:
19563827
16.

A genome-wide association study of a sustained pattern of antidepressant response.

Hunter AM, Leuchter AF, Power RA, Muthén B, McGrath PJ, Lewis CM, Cook IA, Garriock HA, McGuffin P, Uher R, Hamilton SP.

J Psychiatr Res. 2013 Sep;47(9):1157-65. doi: 10.1016/j.jpsychires.2013.05.002. Epub 2013 May 30.

17.

Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.

Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP.

Biol Psychiatry. 2007 Mar 15;61(6):734-42. Epub 2006 Nov 21.

PMID:
17123473
18.

Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.

Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF.

Arch Gen Psychiatry. 2004 Nov;61(11):1163-9.

PMID:
15520364
19.

Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.

Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, Fava M, Trivedi MH, Wisniewski SR, Laje G, Paddock S, McMahon FJ, Manji H, Lipsky RH.

Arch Gen Psychiatry. 2007 Jul;64(7):783-92.

PMID:
17606812
20.

Family history of depression and therapeutic outcome: findings from STAR*D.

Husain MM, Rush AJ, Wisniewski SR, McClintock SM, Fava M, Nierenberg AA, Davis L, Balasubramani GK, Young E, Albala AA, Trivedi MH.

J Clin Psychiatry. 2009 Feb;70(2):185-95. Epub 2008 Dec 2.

PMID:
19192454

Supplemental Content

Support Center